• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估小样本量药物动力学分析中的参数不确定性:基于对数似然概率分布的采样重要性重抽样(LLP-SIR)技术的价值。

Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique.

机构信息

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Bundesstraße 45, 20146, Hamburg, Germany.

出版信息

J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):219-228. doi: 10.1007/s10928-020-09682-4. Epub 2020 Apr 4.

DOI:10.1007/s10928-020-09682-4
PMID:32248328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7289778/
Abstract

Assessing parameter uncertainty is a crucial step in pharmacometric workflows. Small datasets with ten or fewer subjects appear regularly in drug development and therapeutic use, but it is unclear which method to assess parameter uncertainty is preferable in such situations. The aim of this study was to (i) systematically evaluate the performance of standard error (SE), bootstrap (BS), log-likelihood profiling (LLP), Bayesian approaches (BAY) and sampling importance resampling (SIR) to assess parameter uncertainty in small datasets and (ii) to evaluate methods to provide proposal distributions for the SIR. A simulation study was conducted and the 0-95% confidence interval (CI) and coverage for each parameter was evaluated and compared to reference CIs derived by stochastic simulation and estimation (SSE). A newly proposed LLP-SIR, combining the proposal distribution provided by LLP with SIR, was included in addition to conventional SE-SIR and BS-SIR. Additionally, the methods were applied to a clinical dataset. The determined CIs differed substantially across the methods. The CIs of SE, BS, LLP and BAY were not in line with the reference in datasets with ≤ 10 subjects. The best alignment was found for the LLP-SIR, which also provided the best coverage results among the SIR methods. The best overall results regarding the coverage were provided by LLP and BAY across all parameters and dataset sizes. To conclude, the popular SE and BS methods are not suitable to derive parameter uncertainty in small datasets containing ≤ 10 subjects, while best performances were observed with LLP, BAY and LLP-SIR.

摘要

评估参数不确定性是药代动力学工作流程中的关键步骤。在药物开发和治疗应用中,经常会出现包含十个或更少受试者的小数据集,但尚不清楚在这种情况下评估参数不确定性的首选方法。本研究的目的是:(i)系统评估标准误差(SE)、自举(BS)、对数似然分布(LLP)、贝叶斯方法(BAY)和抽样重要性重采样(SIR)在小数据集中评估参数不确定性的性能,以及(ii)评估为 SIR 提供建议分布的方法。进行了一项模拟研究,评估并比较了每个参数的 0-95%置信区间(CI)和覆盖度与通过随机模拟和估计(SSE)得出的参考 CI。除了传统的 SE-SIR 和 BS-SIR 外,还纳入了一种新的 LLP-SIR,该方法将 LLP 提供的建议分布与 SIR 相结合。确定的 CI 在不同方法之间存在显著差异。在包含≤10 个受试者的数据集,SE、BS、LLP 和 BAY 的 CI 与参考值不一致。SIR 方法中, LLP-SIR 的一致性最好,同时也提供了最佳的覆盖结果。在所有参数和数据集大小中, LLP 和 BAY 提供了最佳的覆盖结果。总之,在包含≤10 个受试者的小数据集中,流行的 SE 和 BS 方法不适合用于推断参数不确定性,而 LLP、BAY 和 LLP-SIR 表现最佳。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/25545ffa272e/10928_2020_9682_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/58761a1395ac/10928_2020_9682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/3714f432d897/10928_2020_9682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/842a1f537dc4/10928_2020_9682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/25545ffa272e/10928_2020_9682_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/58761a1395ac/10928_2020_9682_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/3714f432d897/10928_2020_9682_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/842a1f537dc4/10928_2020_9682_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fdf/7289778/25545ffa272e/10928_2020_9682_Fig4_HTML.jpg

相似文献

1
Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique.评估小样本量药物动力学分析中的参数不确定性:基于对数似然概率分布的采样重要性重抽样(LLP-SIR)技术的价值。
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):219-228. doi: 10.1007/s10928-020-09682-4. Epub 2020 Apr 4.
2
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.利用重抽样重要性采样法改进非线性混合效应模型中参数不确定性分布的估计。
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596. doi: 10.1007/s10928-016-9487-8. Epub 2016 Oct 11.
3
An automated sampling importance resampling procedure for estimating parameter uncertainty.一种用于估计参数不确定性的自动采样重要性重采样程序。
J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520. doi: 10.1007/s10928-017-9542-0. Epub 2017 Sep 8.
4
Evaluation of uncertainty parameters estimated by different population PK software and methods.不同群体药代动力学软件和方法所估计的不确定性参数评估。
J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):289-311. doi: 10.1007/s10928-006-9046-9. Epub 2007 Jan 10.
5
dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.dOFV 分布:应用于自举法的非线性混合效应模型中参数不确定性充分性的一种新诊断
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):597-608. doi: 10.1007/s10928-016-9496-7. Epub 2016 Oct 11.
6
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
7
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.线性混合效应模型中用于估计参数不确定性的自助法比较。
Pharm Stat. 2013 May-Jun;12(3):129-40. doi: 10.1002/pst.1561. Epub 2013 Mar 4.
8
Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.两种自举法在非线性混合效应模型中获取非参数参数分布不精确估计的应用。
J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):63-82. doi: 10.1007/s10928-010-9177-x. Epub 2010 Nov 13.
9
Comparative assessment of parameter estimation methods in the presence of overdispersion: a simulation study.存在过度离散情况下参数估计方法的比较评估:一项模拟研究
Math Biosci Eng. 2019 May 16;16(5):4299-4313. doi: 10.3934/mbe.2019214.
10
Uncertainty Computation at Finite Distance in Nonlinear Mixed Effects Models-a New Method Based on Metropolis-Hastings Algorithm.非线性混合效应模型中有限距离处的不确定性计算-基于 Metropolis-Hastings 算法的新方法。
AAPS J. 2024 Apr 23;26(3):53. doi: 10.1208/s12248-024-00905-x.

引用本文的文献

1
A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection.一种专注于准确剂量选择的儿科药代动力学研究设计评估新方法。
Clin Pharmacokinet. 2025 Jun 30. doi: 10.1007/s40262-025-01542-z.
2
Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery-A Population Pharmacokinetic Study.胺碘酮对心脏手术后患者阿哌沙班暴露量的影响——一项群体药代动力学研究
Clin Pharmacokinet. 2025 Jun 5. doi: 10.1007/s40262-025-01534-z.
3
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study.

本文引用的文献

1
Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.采用高吸附膜行连续性静脉-静脉血液透析滤过的患者中,应用药代动力学/药效学群体分析法优化美罗培南剂量方案。
J Antimicrob Chemother. 2019 Oct 1;74(10):2979-2983. doi: 10.1093/jac/dkz299.
2
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.健康人群中替考拉宁静脉给药的群体药代动力学模型,用于评估组织暴露情况。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1097-1106. doi: 10.1007/s00210-019-01647-w. Epub 2019 May 6.
3
模型指导下的接受缓慢延长每日透析(SLEDD)的重症患者美罗培南优化给药策略的识别:一项观察性研究。
Infection. 2025 Apr 25. doi: 10.1007/s15010-025-02504-0.
4
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.在临床实践中,将群体药代动力学建模与精准给药相结合的推荐方法。
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
5
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.TLD-1(一种新型脂质体阿霉素)在 I 期临床试验中的群体药代动力学。
Cancer Chemother Pharmacol. 2024 Sep;94(3):349-360. doi: 10.1007/s00280-024-04679-z. Epub 2024 Jun 15.
6
Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU.严重烧伤 ICU 患者中白蛋白替代对哌拉西林/他唑巴坦药代动力学的影响。
J Antimicrob Chemother. 2024 Feb 1;79(2):262-270. doi: 10.1093/jac/dkad368.
7
Bayesian estimation in NONMEM.贝叶斯估计在 NONMEM 中的应用。
CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):192-207. doi: 10.1002/psp4.13088. Epub 2023 Dec 8.
8
Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.强化头孢洛林给药的关键组分对药代动力学/药效学目标达成的影响。
Clin Pharmacokinet. 2024 Jan;63(1):121-131. doi: 10.1007/s40262-023-01325-4. Epub 2023 Nov 26.
9
Operational characteristics of full random effects modelling ('frem') compared to stepwise covariate modelling ('scm').全随机效应模型(‘frem’)与逐步协变量建模(‘scm’)的操作特点比较。
J Pharmacokinet Pharmacodyn. 2023 Aug;50(4):315-326. doi: 10.1007/s10928-023-09856-w. Epub 2023 Apr 21.
10
Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels.经改良用于儿科患者的血管内微透析导管在健康成人中评估万古霉素血药浓度的初步药代动力学研究。
Clin Pharmacokinet. 2023 Jan;62(1):77-87. doi: 10.1007/s40262-022-01190-7. Epub 2022 Dec 6.
NONMEM Tutorial Part II: Estimation Methods and Advanced Examples.
非房室模型(NONMEM)教程第二部分:估计方法与高级示例。
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):538-556. doi: 10.1002/psp4.12422. Epub 2019 Jun 21.
4
Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.替加环素在接受连续肾脏替代治疗的危重症患者中的应用:一项群体药代动力学研究。
Crit Care. 2018 Dec 17;22(1):341. doi: 10.1186/s13054-018-2278-4.
5
An automated sampling importance resampling procedure for estimating parameter uncertainty.一种用于估计参数不确定性的自动采样重要性重采样程序。
J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520. doi: 10.1007/s10928-017-9542-0. Epub 2017 Sep 8.
6
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.利用重抽样重要性采样法改进非线性混合效应模型中参数不确定性分布的估计。
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596. doi: 10.1007/s10928-016-9487-8. Epub 2016 Oct 11.
7
dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.dOFV 分布:应用于自举法的非线性混合效应模型中参数不确定性充分性的一种新诊断
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):597-608. doi: 10.1007/s10928-016-9496-7. Epub 2016 Oct 11.
8
White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.白皮书:药物/疾病建模和模拟的技术和概念要求及能力框架概览。
CPT Pharmacometrics Syst Pharmacol. 2013 May 1;2(5):e40. doi: 10.1038/psp.2013.16.
9
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.线性混合效应模型中用于估计参数不确定性的自助法比较。
Pharm Stat. 2013 May-Jun;12(3):129-40. doi: 10.1002/pst.1561. Epub 2013 Mar 4.
10
Model-based drug development.基于模型的药物研发。
Clin Pharmacol Ther. 2007 Jul;82(1):21-32. doi: 10.1038/sj.clpt.6100235. Epub 2007 May 23.